Lipella Pharmaceuticals Inc.

Lipella Pharmaceuticals Inc. operated as a clinical-stage biotechnology company headquartered in Pittsburgh, Pennsylvania. The Company developed novel therapies using proprietary liposomal drug delivery technology and advanced multiple drug candidates into FDA-authorized clinical trials, including Phase 2 studies in oral lichen planus and hemorrhagic cystitis. The Company obtained multiple Investigational New Drug authorizations from the U.S. Food and Drug Administration.

In 2022, Lipella completed its initial public offering, and its common stock began trading on the Nasdaq Capital Market under the ticker symbol LIPO.

The Company's lead indications included oral lichen planus, hemorrhagic cystitis, oral graft-versus-host disease, and non-muscle invasive bladder cancer. Lipella also developed intellectual property relating to the diagnosis of interstitial cystitis and completed multiple FDA-authorized clinical studies.

In June 2026, Lipella completed a court-approved sale of its pharmaceutical development programs and associated intellectual property and regulatory assets to XRAIY LLC, and concluded its research and development activities.

This website is maintained as the historical archive of Lipella Pharmaceuticals Inc. and as a source for corporate notices, announcements, SEC filings, publications, and other public disclosures.

Selected Publications

Press Releases & Corporate Announcements

SEC Filings

Lipella Pharmaceuticals Inc.'s public filings are available through the SEC's EDGAR database:
View Lipella Pharmaceuticals Inc. SEC filings

Contact

Email: info@lipella.com

© 2026 Lipella Pharmaceuticals Inc.